A sec­ond Carl Ic­ahn pro­tégé jumps in on SPAC spree, as Alex Den­ner guns for $175M

A sec­ond Carl Ic­ahn pro­tégé is jump­ing in­to the biotech SPAC rush, this time one with a lot more ex­pe­ri­ence — and a lot more of a rep­u­ta­tion — in drug de­vel­op­ment.

Alex Den­ner, the man­ag­ing part­ner at Saris­sa Cap­i­tal and ar­chi­tect of ac­tivist at­tacks at a hand­ful of ma­jor biotechs over the last decade, has filed to raise $175 mil­lion of a spe­cial­ty ac­qui­si­tion com­pa­ny that would fo­cus on “health­care and bio­phar­ma,” with cell and gene ther­a­py gar­ner­ing par­tic­u­lar em­pha­sis in the S-1.  The SPAC will be known as Saris­sa Cap­i­tal Ac­qui­si­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER